Aspirin and Other Antiplatelet Therapy For Secondary Prevention
In secondary prevention among patients who already have a history of stroke, TCI, MI, or unstable angina, 25 randomized trials of various antiplatelet agents (aspirin, dipyridamole [Persantine] , sulfinpyrazone [Anturane] , or suloctidil, either alone or in combination) had been completed by 1988. These trials included a total of approximately 29 ,000 individuals, 18,000 with a history of MI (10 trials),15-27 9 ,000 with a history of stroke or TCI (13 trials),28-43 and 2,000 with unstable angina (two trials).4445 Taken separately, these trials were too small to yield statistically stable results, and, moreover, data-dependent emphasis on some trials and not others might be biased. Taken together, however, an overview, or meta-analysis, of all their results can yield a more statistically stable estimate (i.e., one with less variability due to chance fluctuations in the data) of the effects of antiplatelet therapy and can avoid biases arising from overemphasis on just a few of the trials.
In the recent overview,46 the three main types of endpoints analyzed separately were nonfatal MI, nonfatal stroke, and total cardiovascular death (International Classification of Disease, 9th Revision, 390-459, 530-539, and 798-799, which includes not only all forms of cardiac or vascular disease but also deaths from peptic ulcers or from unknown causes), together with a combined category of vascular events (i.e., any of the three main types of end points). Overall, the proportional reductions were greater in nonfatal MI and in nonfatal stroke than in cardiovascular death, but, for each of the three separate end points, the reduction observed among those allocated to antiplatelet treatment was highly significant (p<0.0001). As expected in these highrisk populations, the proportion of deaths attributed to noncardiovascular causes was small and was not significantly affected by antiplatelet therapy. Therefore, total mortality was also very significantly improved (p<0.0001). For statistical stability, the comparisons of different trial results are based primarily on all vascular events, not just vascular for major bleeds (31 vs. 33) and no evidence of any adverse effect on nonvascular deaths (one aspirin vs. seven placebo, p>0.05). With respect to total reinfarction, fatal or not, there were 156 reported events in the aspirin group compared with 284 among those on placebo. This difference was highly statistically significant. Finally, 47 strokes were confirmed in the aspirin group compared with 81 in placebo, a reduction that was also statistically significant (p =0.003). The protective effect of aspirin against reinfarction and stroke included both fatal and nonfatal events (Table 3) , and was seen whether or not streptokinase was given. Strokes were subdivided according to whether or not the event was confirmed as hemorrhagic, as well as by the probable severity of any residual impairment. Although fibrinolytic treatment with agents such as streptokinase does not appear to have any significant effect on the overall incidence of stroke,51 this may merely reflect a balance between risks and benefits on strokes of differing etiologies. Specifically, fibrinolytic treatment may prevent some occlusive strokes, and does appear to cause some hemorrhagic strokes (about one or two per 1,000 patients treated) within the first 24-48 hours after treatment. There was, in ISIS-2, a nonsignificant tendency for aspirin to aggravate this early fibrinolytic hazard, but even if this effect is real, it is outweighed by the protective effects of aspirin against occlusive stroke and against stroke, as a whole. or cardiovascular death), there was a statistically significant 18+7% reduction among those on aspirin. There was a highly significant 44% reduction in the overall risk of MI. Most of the infarcts that were prevented were, however, nonfatal (129 vs. 213) and, although there was a conventionally significant reduction in the number of deaths that were definitely attributed to MI by the end points committee (10 vs. 26), there was no difference in the numbers of deaths attributed to "other ischemic heart disease" (24 vs. 25 ) and a nonsignificant excess of "sudden death, cause unknown" (22 vs. 12), (some of which may have been due to coronary artery occlusion) and of stroke deaths (10 vs. seven). Thus, the reduction in total cardiovascular mortality was not significant (2+15%), although the standard deviation is too large for this finding to be reliable evidence of lack of benefit. There appeared to be a slightly increased risk of total stroke among those taking aspirin (19±15%), but this was not statistically significant, and did not become significant even if attention was restricted to the small subgroup of hemorrhagic strokes (23 vs. 12). There was no significant difference in nonvascular mortality (124 vs. 133).
The British Doctors' Trial randomized 5,139 male British physicians initially aged 50-78 years. It tested 500 mg of aspirin daily using an open design, where the control group was merely asked to avoid aspirin and all products containing aspirin rather than to take a placebo. There was no significant difference for the combined end point of important vascular events, for MI, for stroke, or for total vascular mortality. When strokes were subdivided by etiology, as well as by the severity of any residual disability for nonfatal events, the only conventionally significant result was an increased risk of disabling strokes among those in the aspirin group, and even that was not clearly significant (p=0.05). Even if this apparent excess is at least partly real, it is difficult to know whether it reflects more severe strokes among those taking aspirin (perhaps because hemorrhagic strokes are particularly hazardous), or some bias introduced by the subjective nature of the assessment of residual impairment, which was done through self-reports, without placebo control. These two trials of primary prevention had a number of differences in their design. First, with respect to dosage and frequency of administration, the US study tested one 325 mg tablet every other day, whereas the British trial tested 500 mg of aspirin daily. The US study was double blind and placebo controlled, and the UK trial used a singleblind and open design. In the US trial, 86% in the aspirin group took the drug and 14% in the placebo group reported taking aspirin after 60.2 months of follow-up, resulting in a difference of 72% in the proportions using aspirin. In the British trial, 70% of the aspirin takers took the drug and 2% of those assigned to aspirin avoidance reported taking aspirin, resulting in a difference in the proportions using aspirin of 68% after the first 36 months of a 6-year follow-up, which is similar to the 72% seen in the US study. The most obvious difference between the two studies is in their sample sizes, with 22,071 subjects randomized in the US trial and 5,139 in the British trial. This corresponds to a large difference in the number of nonfatal MIs recorded in the two studies, but because the British doctors were older, the numbers of deaths in the two trials were similar.
An early overview56 of these two trials of primary prevention showed an overall 33% reduction in nonfatal MI that was highly significant (p <0.0002) but no significant difference in total or cardiovascular mortality. That overview was based on only preliminary data from the US trial, but a repeat analysis, based on final data, gives virtually identical results, in particular, a 32% reduction in the odds of suffering a first nonfatal MI (Table 5 , Figure 1 ).
Side Effects
Although the beneficial effects of aspirin on cyclooxygenase-dependent platelet aggregation may be approximately equivalent over a dose range of at least 100-1,500 mg daily, some of the main side effects are dose related. 57 The recently completed UK-TIA trial tested two daily dosages of aspirin versus placebo among 2,345 patients with a history of TCI or mild ischemic stroke.29 It was, therefore, possible to compare directly the frequencies of side effects reported at 300 mg/day and at 1,200 mg/day (Table 6 ). For each category of symptom, including indigestion, nausea, or heartburn; constipation; any gastrointestinal (GI) bleed; and serious GI bleed (i.e., requiring hospital admission), the percentage of participants reporting it was lowest in the placebo group, somewhat higher in the group receiving 300 mg/day, and highest of all among those receiving 1,200 mg daily. Moreover, for symptoms of GI distress as well as for any GI bleed, the differences between the low-and high-dose groups were statistically significant. In the Physicians' Health Study, however, which tested a regimen of 325 mg of aspirin on alternate days, such symptoms were reported by 26.1% of the active group and 25.6% of the placebo group, a nonsignificant absolute difference of only 0.5±1% of such symptoms attributable to the aspirin. This very low rate of GI discomfort attributable to aspirin, in the US study, may be partly due to the alternate-day schedule of administration that may allow the gastric mucosa to heal between doses,58 as well as to a prerandomization run-in that excluded those unable to tolerate the drug. Even with 325 mg on alternate days, however, some gastrotoxicity may remain and, in the Physicians' Health Study, there was a nonsignificant (0.2±0.2%) excess of peptic ulcer among those allocated aspirin. This gastrotoxicity might be further reduced by the alternate-day use of low-dose enteric-coated (instead of regular, with or without buffering) aspirin, but no results from large-scale, corresponds to an approximate 20% decrease in the incidence of coronary heart disease.61 For blood pressure, overviews of the randomized trials62-63 suggested that a 5-or 6-mm decrease in diastolic blood pressure through pharmacologic therapy among those with mild to moderate hypertension results in about a 10-15% lower risk of coronary heart disease, as well as a 40% reduction in risk of stroke, and observational epidemiologic studies suggest that a long-term difference of 5-6 mm would produce a 20-25% reduction in coronary heart disease. Finally, in middle age, cessation of cigarette smoking yields an approximate 50% decrease in risk of coronary heart disease, perhaps within only a few months of cessation.64 It would be particularly unfortunate if middle-aged smokers took aspirin instead of quitting smoking because, even if aspirin does have some effect on the risk of coronary heart disease in smokers, the reduction in coronary heart disease from quitting smoking would probably exceed any protective effect of aspirin. Further, a continuing smoker will still remain exposed to a major risk factor for stroke,65-66 cancer,66-67 and chronic lung disease. 66 Thus, low-dose aspirin should be a possible adjunct, not an alternative, to coronary risk factor management and, in view of its possible side effects, should be prescribed for long-term use only by a physician or other health care provider. For primary prevention, aspirin is unlikely to be of much net benefit in young adults, except perhaps those few with genetic factors that greatly increase their risk. Among middle-aged and older adults, any decision to use aspirin should consider the cardiovascular risk profile of the patient. In most circumstances it would be reasonable to assume that aspirin will reduce nonfatal MI by about one third, with an effect that is still favorable (but probably not as large as one third) on death from coronary heart disease. No such generalization is yet possible, however, regarding the net effect on fatal or nonfatal strokes. In the primary prevention trials, the apparent effect on stroke was not favorable, perhaps because of a small number of hemorrhagic strokes, and the prescription of long-term aspirin might, therefore, be restricted to circumstances where the incidence of MI is expected to be so high that even the moderate reduction that aspirin can be expected to produce is likely to outweigh any possible adverse effect on stroke or other conditions. For secondary prevention, the decision is much easier, for among patients with a history of occlusive stroke, TCI, or coronary artery disease, aspirin definitely reduces the subsequent incidence of both stroke and MI and definitely reduces subsequent mortality. This reduction is particularly clear in acute MI. Indeed, treatment of 100 acute MI patients with 1 month of aspirin, can preclude approximately two deaths and one nonfatal event.5' But, this is also true for patients with unstable angina and for those past the acute phase; indeed, for MI patients, continuation of low dose aspirin for 1 or 2 years could probably preclude another two deaths and three nonfatal events,56 making the total avoided by early and late MI treatment equal to four fatal and four nonfatal events.51 These are substantial benefits from so simple a treatment, and the uncertainties remaining about whether or when to use antiplatelet therapy in primary prevention do not imply uncertainty regarding its value in many types of secondary prevention.
